NCT04972110 - Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumor, Adult

Interventions

DRUG

RP-3500 (camonsertib)

RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)

Trial Locations (13)

Participating Site #1026, New York

Participating Site # 1008, New York

Participating Site #1009, Baltimore

Participating Site #1017, Jacksonville

Participating Site #1015, Ann Arbor

Participating Site # 1016, Rochester

Participating Site # 1001, Houston

Participating Site #1028, Aurora

Participating Site # 1013, Salt Lake City

Participating Site #1025, San Francisco

Participating Site #1018, Phoenix

Participating Site #1029, Eugene

Participating Site #1012, New Haven